financetom
Business
financetom
/
Business
/
J.M. Smucker Cuts FY25 Outlook Following Q1 Earnings: Read Why
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
J.M. Smucker Cuts FY25 Outlook Following Q1 Earnings: Read Why
Aug 29, 2024 9:28 AM

The J.M. Smucker Company shares are trading lower on Wednesday.

The company reported first-quarter adjusted earnings per share of $2.44 (+10% Y/Y), beating the analyst consensus estimate of $2.17. Quarterly sales of $2.125 billion (+18% Y/Y) slightly missed the Street view of $2.133 billion.

“These results are driven by the focus we have established and progress we have made in delivering our core business, successfully integrating Hostess Brands, and achieving our goals for transformation, cost discipline, and cash generation,” said Mark Smucker, Chair of the Board, President and Chief Executive Officer.

Also Read: Bath & Body Works’ Q2 EPS Manages To Beat, But Sales Stumble – CEO Promises To Navigate Retail Storms

Gross profit rose by $142.4 million, or 22%. Adjusted gross profit increased $188.1 million, or 29%.

This increase was largely due to the acquisition of Hostess Brands and positive volume/mix effects, though the impact of divestitures partially offset it.

Operating cash flow was $172.9 million, down from $217.9 million in the prior year, primarily due to increased cash needed for working capital, though partially offset by higher net income adjusted for noncash items.

Outlook: J.M. Smucker projects FY25 Adjusted EPS to range $9.60 to $10.00, compared to the prior estimate of $9.80 to $10.20 and the $10.03 estimate.

The company also expects net sales growth of 8.5% to 9.5%, down from the previous range of 9.5% to 10.5%. Comparable net sales is expected to increase approximately 0.5%-1.5%.

“The updated net sales guidance reflects an ongoing dynamic consumer environment driven by inflationary pressures and diminished discretionary income affecting the dog snacks and sweet baked goods categories, and the anticipated impacts of elasticity of demand within our coffee portfolio due to additional pricing actions as a result of higher than expected green coffee costs, partially offset by increased expectations for Uncrustables sandwiches,” the company said.

Price Action: SJM shares are trading lower by 4.59% to $115.16 at last check Wednesday.

Read Next:

Nasdaq, S&P 500 Futures Flatline As Traders Await Earnings Report From AI Barometer Nvidia: Fund Manager Says Market Could Hold Up Until Presidential Election

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Nissan returns to operating profit in second quarter
Nissan returns to operating profit in second quarter
Nov 6, 2025
YOKOHAMA, Japan, Nov 6 (Reuters) - Nissan Motor ( NSANF ) swung back to an operating profit in the second quarter on Thursday, reporting its best quarterly result in more than a year due to efforts to reduce fixed costs as part of its turnaround plan and stronger sales in North America. Nissan ( NSANF ) booked 51.5 billion yen...
Exxon Mobil sees first gas from Greece project in early 2030s 
Exxon Mobil sees first gas from Greece project in early 2030s 
Nov 6, 2025
ATHENS, Nov 6 (Reuters) - Exxon Mobil ( XOM ) expects first natural gas from its newly-announced offshore Greece project in the early 2030s if all goes well, John Ardill, the company's head of global exploration, told Reuters. The project, in partnership with Greece's Energean and Helleniq Energy will involve investment of between $50 million and $100 million, he said....
Corcept Therapeutics Insider Sold Shares Worth $1,479,816, According to a Recent SEC Filing
Corcept Therapeutics Insider Sold Shares Worth $1,479,816, According to a Recent SEC Filing
Nov 6, 2025
03:23 AM EST, 11/06/2025 (MT Newswires) -- Sean Maduck, President, Corcept Endocrinology, on November 03, 2025, sold 20,000 shares in Corcept Therapeutics ( CORT ) for $1,479,816. Following the Form 4 filing with the SEC, Maduck has control over a total of 117,621 common shares of the company, with 7,904 shares held directly and 109,717 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1088856/000119312525267542/xslF345X05/ownership.xml...
Corcept Therapeutics Insider Sold Shares Worth $2,983,119, According to a Recent SEC Filing
Corcept Therapeutics Insider Sold Shares Worth $2,983,119, According to a Recent SEC Filing
Nov 6, 2025
03:24 AM EST, 11/06/2025 (MT Newswires) -- Joseph K Belanoff, Director, Chief Executive Officer, on November 03, 2025, sold 40,000 shares in Corcept Therapeutics ( CORT ) for $2,983,119. Following the Form 4 filing with the SEC, Belanoff has control over a total of 2,741,370 common shares of the company, with 2,741,370 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1088856/000119312525267545/xslF345X05/ownership.xml ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved